Stephen Miller
Acute Care · Knoxville, TNNPI 1851381198
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $69,132 of the $108,446 with a category attached, or 63.7%. 45 manufacturers reported payments, led by Bayer at 29.7% of the total. Among acute care clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,044 payments — averaging $103.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$32K
- Scpharmaceuticals Inc.$23K
- Esperion Therapeutics, Inc.$12K
- Daiichi Sankyo Inc.$9K
- Boehringer Ingelheim$5K
- AstraZeneca$5K
- plus $22K from 39 others
What the payments were for
- Consulting fees$4360%
- Speaking & faculty fees$69,13264%
- Travel & lodging$17,27716%
- Food & beverage$21,40820%
- Education$1930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$31,328
- FUROSCIX$23,170
- NEXLIZET$11,638
- NEXLETOL$11,638
- INJECTAFER$8,534
- JARDIANCE$6,675
- FARXIGA$4,236
- AccuCinch$2,541
- Reveal LINQ$1,050
- Barostim Neo System$880
- FFRct$362
- CT THROMBECTOMY SYSTEM KIT$259
- FLOWTRIEVER CATHETER, S$259
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$152
- CARDIOMEMS$148
- ENROUTE Transcarotid Stent$134
- ENROUTE Transcarotid Neuroprotection System$134
- LINQ II$127
- Repatha$126
- WatchPATONE$124
How this compares
$108,446 in reported general payments places this provider in the 95th percentile of 738 acute care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 625 | $577,535 |
| Repatha SureclickEvolocumab | 321 | $258,401 |
| AdempasRiociguat | 12 | $169,052 |
| EntrestoSacubitril/Valsartan | 175 | $157,186 |
| XareltoRivaroxaban | 153 | $154,528 |
| JardianceEmpagliflozin | 139 | $130,980 |
| BrilintaTicagrelor | 149 | $104,480 |
| FuroscixFurosemide | 12 | $83,313 |
| VascepaIcosapent Ethyl | 119 | $70,084 |
| FarxigaDapagliflozin Propanediol | 72 | $58,453 |
| MultaqDronedarone Hcl | 39 | $40,987 |
| NexletolBempedoic Acid | 47 | $39,905 |
| Praluent PenAlirocumab | 61 | $34,570 |
| NexlizetBempedoic Acid/Ezetimibe | 50 | $30,905 |
| OzempicSemaglutide | 18 | $22,841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,456 | $577,535625 claims |
| BayerAdempas, Kerendia | $32,261 | $176,01823 claims |
| AstraZenecaBrilinta, Farxiga | $4,903 | $162,933221 claims |
| NovartisEntresto | $1,538 | $157,186175 claims |
| Johnson & JohnsonXarelto | $1,023 | $154,528153 claims |
| Boehringer IngelheimJardiance | $4,918 | $130,980139 claims |
| Scpharmaceuticals Inc.Furoscix | $23,441 | $83,31312 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $12,349 | $70,81097 claims |
| Sanofi-aventis U.S. LLCMultaq | $165 | $40,98739 claims |
| Novo NordiskOzempic | $415 | $22,84118 claims |
| Lilly USA, LLCMounjaro | $2,275 | $18,11416 claims |
| MerckVerquvo | $378 | $10,50214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 738 acute care providers in Tennessee.
Other acute care in Knoxville
- Timothy BallardKnoxville$47K
- Kimberly SmithKnoxville$26K
- Sydney StooksburyKnoxville$5K
- William StaffordKnoxville$5K
- Haley HoyNashville$368K
- Anne AlexandrovMemphis$110K
- Shannon GraceNashville$57K
- Kelsey MartinNashville$42K
- Barbara BrownNashville$36K
- Michelle GoochChattanooga$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.